Role of Serum Metabolites in Mediating the Effect of Circulating Inflammatory Proteins on NK/T Cell Lymphoma.

IF 3.2 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Dian Lou, Chen Zhang, Li Liu, Zhuojun Shi, Zhuo Wan, Weiwei Qin
{"title":"Role of Serum Metabolites in Mediating the Effect of Circulating Inflammatory Proteins on NK/T Cell Lymphoma.","authors":"Dian Lou, Chen Zhang, Li Liu, Zhuojun Shi, Zhuo Wan, Weiwei Qin","doi":"10.2174/0109298673456330260925101143","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>NK/T Cell Lymphomas (NKTCL) are highly aggressive types of Non-Hodgkin's Lymphoma (NHL) that have a predilection for Asian and South American populations. Identifying new drug targets or prognostic markers is essential for developing future strategies for NKTCL treatment.</p><p><strong>Methods: </strong>This study employed a two-step and bidirectional Mendelian Randomization (MR) study with an Inverse Variance Weighted (IVW) approach to investigate the potential association of Circulating Inflammatory Proteins (CIPs) with NKTCL and the mediation effect of serum metabolites in the relationship between CIPs and NKTCL. Data on 91 CIPs from a proteomic study of 14,824 individuals conducted with the Olink Target platform were collected. Genetic information for NKTCL was obtained from the finngen_ R10_CD2_TNK_LYMPHOMA, including 363 cases and 324,650 controls. Data for 1,091 plasma metabolites and 309 metabolite ratios (Ebi-a- GCST90199621 to Ebia- GCST90201020) were derived from the GWAS Catalog.</p><p><strong>Results: </strong>MR analyses identified 4 plasma proteins significantly associated with NKTCL. Increased levels of TGF-α and TNFRSF9 were associated with increased NKTCL risk, with Odds Ratios (OR) of 1.6388 (95% CI 1.0158-2.6440) and 1.6863 (95% CI 1.1757-2.4187), respectively. Conversely, LIF-R (OR 0.6265, 95% CI 0.4427-0.8866) and SULT1A1 (OR 0.5425, 95% CI 0.3758-0.7833) exhibited protective effects. Notably, none of these proteins showed evidence of reverse causality. Furthermore, the mediation MR suggested that the effect of TNFRSF9 on NKTCL (total effect IVW: OR = 1.6863, 95% CI 1.1757-2.4187, P = 0.010) was partially mediated by Isobutyrylcarnitine (C4) levels (0.739, 95% CI 0.609-0.895, P = 0.002), accounting for 5.77% of the total effect.</p><p><strong>Discussion: </strong>This MR study suggests that CIPs may be associated with NKTCL pathogenesis and proposes that metabolite-mediated pathways represent a potential novel mechanistic link. It provides preliminary evidence consistent with serum metabolites playing a role as mediators in this relationship. These findings highlight the therapeutic potential of targeting specific metabolic pathways in NKTCL.</p><p><strong>Conclusion: </strong>Our proteome-wide MR analysis suggests an association between CIPs and NKTCL, which may be mediated by serum metabolites.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673456330260925101143","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: NK/T Cell Lymphomas (NKTCL) are highly aggressive types of Non-Hodgkin's Lymphoma (NHL) that have a predilection for Asian and South American populations. Identifying new drug targets or prognostic markers is essential for developing future strategies for NKTCL treatment.

Methods: This study employed a two-step and bidirectional Mendelian Randomization (MR) study with an Inverse Variance Weighted (IVW) approach to investigate the potential association of Circulating Inflammatory Proteins (CIPs) with NKTCL and the mediation effect of serum metabolites in the relationship between CIPs and NKTCL. Data on 91 CIPs from a proteomic study of 14,824 individuals conducted with the Olink Target platform were collected. Genetic information for NKTCL was obtained from the finngen_ R10_CD2_TNK_LYMPHOMA, including 363 cases and 324,650 controls. Data for 1,091 plasma metabolites and 309 metabolite ratios (Ebi-a- GCST90199621 to Ebia- GCST90201020) were derived from the GWAS Catalog.

Results: MR analyses identified 4 plasma proteins significantly associated with NKTCL. Increased levels of TGF-α and TNFRSF9 were associated with increased NKTCL risk, with Odds Ratios (OR) of 1.6388 (95% CI 1.0158-2.6440) and 1.6863 (95% CI 1.1757-2.4187), respectively. Conversely, LIF-R (OR 0.6265, 95% CI 0.4427-0.8866) and SULT1A1 (OR 0.5425, 95% CI 0.3758-0.7833) exhibited protective effects. Notably, none of these proteins showed evidence of reverse causality. Furthermore, the mediation MR suggested that the effect of TNFRSF9 on NKTCL (total effect IVW: OR = 1.6863, 95% CI 1.1757-2.4187, P = 0.010) was partially mediated by Isobutyrylcarnitine (C4) levels (0.739, 95% CI 0.609-0.895, P = 0.002), accounting for 5.77% of the total effect.

Discussion: This MR study suggests that CIPs may be associated with NKTCL pathogenesis and proposes that metabolite-mediated pathways represent a potential novel mechanistic link. It provides preliminary evidence consistent with serum metabolites playing a role as mediators in this relationship. These findings highlight the therapeutic potential of targeting specific metabolic pathways in NKTCL.

Conclusion: Our proteome-wide MR analysis suggests an association between CIPs and NKTCL, which may be mediated by serum metabolites.

血清代谢物在循环炎性蛋白介导NK/T细胞淋巴瘤中的作用
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current medicinal chemistry
Current medicinal chemistry 医学-生化与分子生物学
CiteScore
8.60
自引率
2.40%
发文量
468
审稿时长
3 months
期刊介绍: Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书